Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants with advanced or metastatic esophageal cancer.

ABSTRACT:

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC12861989 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature